Clinical Trial Update: Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating vorinostat in combination with bortezomib for relapsed or refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Vorinostat (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma | Phase 1 | Status: COMPLETED